Existence_NN of_IN Transdominant_NP and_CC Potentiating_NP Mutants_NP of_IN UL9_NP ,_, the_DT Herpes_NP Simplex_NP Virus_NP Type_NP 1_CD Origin-Binding_NN Protein_NP ,_, Suggests_VBZ that_IN Levels_NP of_IN UL9_NP Protein_NP May_MD Be_VB Regulated_JJ during_IN Infection_NP UL9_NP is_VBZ a_DT multifunctional_JJ protein_NN required_VBN for_IN herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) replication_NN in_IN vivo_RB ._SENT UL9_NP is_VBZ a_DT member_NN of_IN the_DT superfamily_NN II_CD helicases_NNS and_CC exhibits_NNS helicase_NN and_CC origin-binding_NN activities_NNS ._SENT We_PP have_VBP previously_RB shown_VBN that_IN mutations_NNS in_IN the_DT conserved_VBN helicase_NN motifs_NNS of_IN UL9_NP can_MD have_VB either_CC a_DT transdominant_NN or_CC potentiating_VBG effect_NN on_IN the_DT plaque-forming_JJ ability_NN of_IN infectious_JJ DNA_NN from_IN wild-type_NN virus_NN (_( A._NP J._NP Malik_NP and_CC S._NP K._NP Weller_NP ,_, J._NP Virol_NP ._SENT 70:7859-7866_CD ,_, 1996_CD )_) ._SENT In_IN this_DT paper_NN ,_, the_DT mechanisms_NNS of_IN transdominance_NN and_CC potentiation_NN are_VBP explored_VBN ._SENT We_PP show_VBP that_IN the_DT motif_NN V_NN mutant_JJ protein_NN containing_VBG a_DT G_NN to_TO A_DT substitution_NN at_IN residue_NN 354_CD is_VBZ unstable_JJ when_WRB expressed_VBN by_IN transfection_NN and_CC is_VBZ either_RB processed_VBN to_TO a_DT 38-kDa_JJ N-terminal_JJ fragment_NN or_CC degraded_VBD completely_RB ._SENT The_DT overexpression_NN of_IN the_DT MV_NP mutant_JJ protein_NN is_VBZ able_JJ to_TO influence_VB the_DT steady-state_NN protein_NN levels_NNS of_IN wild-type_NN UL9_NN and_CC to_TO override_VB the_DT inhibitory_JJ effects_NNS of_IN wild-type_NN UL9_NP ._SENT Potentiation_NN correlates_NNS with_IN the_DT ability_NN of_IN the_DT UL9_NP variants_NNS containing_VBG the_DT G354A_NP mutation_NN to_TO be_VB processed_VBN or_CC degraded_VBN to_TO the_DT 38-kDa_JJ form_NN ._SENT We_PP propose_VBP that_IN the_DT MV_NP mutant_JJ protein_NN is_VBZ able_JJ to_TO interact_VB with_IN full-length_JJ UL9_NP and_CC that_IN this_DT interaction_NN results_NNS in_IN a_DT decrease_NN in_IN the_DT steady-state_NN levels_NNS of_IN UL9_NP ,_, which_WDT in_IN turn_NN leads_NNS to_TO enhanced_JJ viral_JJ infection_NN ._SENT Furthermore_RB ,_, we_PP demonstrate_VBP that_DT inhibition_NN of_IN HSV-1_JJ infection_NN can_MD be_VB obtained_VBN by_IN overexpression_NN of_IN full-length_JJ UL9_NP ,_, the_DT C-terminal_JJ third_NN of_IN the_DT protein_NN containing_VBG the_DT origin-binding_JJ domain_NN ,_, or_CC the_DT N-terminal_JJ two-thirds_NNS of_IN UL9_NP containing_VBG the_DT conserved_VBN helicase_NN motifs_NNS and_CC the_DT putative_JJ dimerization_NN domain_NN ._SENT Our_PP$ results_NNS suggest_VBP that_IN transdominance_NN can_MD be_VB mediated_VBN by_IN overexpression_NN ,_, origin-binding_VBG activity_NN ,_, and_CC dimerization_NN ,_, whereas_IN potentiation_NN is_VBZ most_RBS likely_RB caused_VBN by_IN the_DT ability_NN of_IN the_DT UL9_NP MV_NP mutant_NN to_TO influence_VB the_DT steady-state_NN levels_NNS of_IN wild-type_NN UL9_NP ._SENT Taken_VBN together_RB ,_, the_DT results_NNS presented_VBN in_IN this_DT paper_NN suggest_VBP that_IN the_DT regulation_NN of_IN steady-state_NN levels_NNS of_IN UL9_NP may_MD play_VB an_DT important_JJ role_NN in_IN controlling_VBG viral_JJ infection_NN ._SENT The_DT UL9_NP gene_NN is_VBZ required_VBN for_IN herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) replication_NN in_IN vivo_RB ._SENT The_DT UL9_NP protein_NN is_VBZ a_DT dimer_NN in_IN solution_NN and_CC exhibits_NNS helicase_NN ,_, ATPase_NP ,_, and_CC origin-binding_NN activities_NNS ._SENT UL9_NP is_VBZ believed_VBN to_TO play_VB a_DT key_JJ role_NN in_IN the_DT initiation_NN of_IN HSV-1_JJ replication_NN by_IN binding_VBG the_DT HSV-1_JJ origin_NN of_IN replication_NN via_IN its_PP$ C-terminal_JJ domain_NN and_CC unwinding_VBG it_PP in_IN the_DT presence_NN of_IN ATP_NP and_CC ICP8_NP ,_, the_DT HSV-1_JJ single-stranded_JJ DNA_NN binding_VBG protein_NN ._SENT It_PP is_VBZ likely_JJ that_IN UL9_NP plays_VBZ an_DT important_JJ role_NN in_IN the_DT assembly_NN of_IN the_DT viral_JJ replisome_NN through_IN its_PP$ interactions_NNS with_IN other_JJ viral_JJ replication_NN proteins_NNS ._SENT UL9_NP is_VBZ a_DT member_NN of_IN the_DT superfamily_NN II_CD helicases_NNS ._SENT The_DT conserved_VBN helicase_NN motifs_NNS that_WDT are_VBP characteristic_JJ of_IN this_DT superfamily_NN are_VBP positioned_VBN within_IN the_DT N-terminal_JJ domain_NN of_IN the_DT protein_NN ._SENT Genetic_JJ studies_NNS have_VBP previously_RB shown_VBN that_IN conserved_VBN residues_NNS within_IN the_DT helicase_NN motifs_NNS are_VBP essential_JJ for_IN HSV-1_JJ replication_NN in_IN vivo_RB ;_: most_RBS engineered_JJ motif_NN mutants_NNS fail_VBP to_TO complement_VB the_DT growth_NN of_IN hr94_NN ,_, a_DT UL9_NP null_JJ virus_NN ._SENT Furthermore_RB ,_, biochemical_JJ analysis_NN showed_VBD a_DT correlation_NN between_IN the_DT failure_NN to_TO complement_VB hr94_NN and_CC the_DT lack_NN of_IN helicase_NN activity_NN ,_, indicating_VBG that_IN helicase_NN activity_NN is_VBZ essential_JJ for_IN UL9_NP function_NN ._SENT Interestingly_RB ,_, a_DT truncated_JJ form_NN of_IN UL9_NP originating_VBG from_IN a_DT unique_JJ transcript_NN within_IN the_DT UL9_NP open_JJ reading_NN frame_NN designated_VBN UL8.5_NP or_CC OBPC_NP has_VBZ been_VBN observed_VBN ._SENT OBPC_NP encompasses_VBZ the_DT 480_CD C-terminal_JJ amino_NN acids_NNS of_IN UL9_NP ._SENT It_PP is_VBZ able_JJ to_TO bind_VB the_DT origin_NN of_IN replication_NN and_CC localizes_VBZ to_TO the_DT nucleus_NN ,_, but_CC its_PP$ significance_NN for_IN the_DT biology_NN of_IN the_DT HSV-1_NP is_VBZ not_RB well_RB understood_VBN ._SENT Several_JJ lines_NNS of_IN evidence_NN indicate_VBP that_DT overexpression_NN of_IN UL9_NP can_MD inhibit_VB HSV-1_JJ infection_NN ._SENT We_PP previously_RB showed_VBD that_IN cell_NN lines_NNS containing_VBG a_DT low_JJ copy_NN number_NN of_IN the_DT wild-type_JJ UL9_NP gene_NN could_MD efficiently_RB complement_VB hr94_NN ._SENT whereas_IN cell_NN lines_NNS harboring_VBG a_DT high_JJ copy_NN number_NN exhibited_VBD lower_JJR levels_NNS of_IN complementation_NN ._SENT In_IN addition_NN ,_, cell_NN lines_NNS harboring_VBG a_DT high_JJ copy_NN number_NN of_IN the_DT UL9_NP gene_NN were_VBD found_VBN to_TO inhibit_VB wild-type_JJ HSV-1_JJ infection_NN ._SENT Furthermore_RB ,_, the_DT cotransfection_NN of_IN wild-type_JJ infectious_JJ DNA_NN with_IN an_DT excess_NN of_IN plasmid_NN encoding_VBG wild-type_NP UL9_NP reduced_VBD the_DT number_NN of_IN plaques_NNS observed_VBD compared_VBN to_TO transfection_NN of_IN wild-type_JJ infectious_JJ DNA_NN alone_RB ._SENT The_DT inhibitory_JJ effect_NN of_IN wild-type_JJ UL9_NP overexpression_NN is_VBZ mediated_VBN at_IN least_JJS in_IN part_NN by_IN the_DT origin-specific_JJ DNA_NN binding_VBG function_NN of_IN UL9_NP ,_, harbored_VBN in_IN the_DT C-terminal_JJ domain_NN (_( UL9_NP CTD_NP )_) ._SENT In_IN a_DT plaque_NN reduction_NN assay_NN ,_, UL9_NP CTD_NP severely_RB reduces_VBZ the_DT efficiency_NN of_IN plaque_NN formation_NN and_CC is_VBZ thus_RB considered_VBN transdominant_NN (_( dominant_JJ negative_NN )_) ._SENT The_DT OB_NP mutation_NN which_WDT disrupts_VBZ the_DT origin-binding_JJ activity_NN of_IN UL9_NP reverses_VBZ the_DT inhibitory_JJ effect_NN of_IN wild-type_NP UL9_NP as_RB well_RB as_IN the_DT transdominant_JJ effect_NN of_IN UL9_NP CTD_NP ._SENT The_DT inhibitory_JJ properties_NNS of_IN the_DT overexpressed_JJ wild-type_NN UL9_NN are_VBP consistent_JJ with_IN a_DT model_NN in_IN which_WDT HSV-1_NP DNA_NP replication_NN occurs_VBZ in_IN two_CD steps_NNS or_CC stages_NNS ._SENT According_VBG to_TO this_DT model_NN ,_, early_RB in_IN infection_NN HSV-1_JJ replication_NN initiates_NNS by_IN a_DT UL9-dependent_JJ process_NN at_IN one_CD or_CC more_JJR origins_NNS of_IN replication_NN (_( stage_NN I_CD )_) ._SENT Later_RBR in_IN infection_NN ,_, replication_NN proceeds_NNS in_IN an_DT origin-independent_JJ manner_NN (_( stage_NN II_CD )_) ._SENT We_PP have_VBP proposed_VBN that_IN ,_, if_IN UL9_NP remains_VBZ bound_VBN to_TO the_DT origin_NN of_IN replication_NN late_RB in_IN infection_NN ,_, it_PP may_MD inhibit_VB the_DT transition_NN between_IN stage_NN I_PP and_CC stage_VB II_NP ._SENT Consistent_JJ with_IN this_DT model_NN ,_, studies_NNS with_IN temperature-sensitive_NN UL9_NN mutants_NNS indicate_VBP that_IN UL9_NP is_VBZ essential_JJ for_IN the_DT early_JJ stages_NNS of_IN HSV-1_JJ replication_NN and_CC appears_VBZ to_TO be_VB dispensable_JJ for_IN the_DT later_JJR ones_NNS ._SENT According_VBG to_TO this_DT scenario_NN ,_, we_PP speculate_VBP that_IN it_PP may_MD be_VB necessary_JJ to_TO downregulate_VB the_DT levels_NNS of_IN UL9_JJ protein_NN during_IN stage_NN II_NP in_IN order_NN for_IN infection_NN to_TO proceed_VB ._SENT The_DT characterization_NN of_IN transdominant_JJ (_( dominant_JJ negative_NN )_) mutants_NNS is_VBZ a_DT widely_RB employed_VBN genetic_JJ approach_NN to_TO gain_VB insight_NN into_IN protein_NN function_NN ._SENT Mutations_NNS in_IN UL9_JJ helicase_NN motifs_NNS I_PP ,_, Ia_NP ,_, II_NP ,_, and_CC VI_NP were_VBD previously_RB shown_VBN to_TO be_VB transdominant_JJ in_IN a_DT plaque_NN reduction_NN assay_NN ._SENT UL9_JJ mutant_JJ proteins_NNS bearing_VBG mutations_NNS in_IN helicase_NN motifs_NNS I_PP ,_, Ia_NP ,_, II_NP ,_, and_CC VI_NP are_VBP able_JJ to_TO dimerize_VB and_CC bind_VB the_DT origin_NN of_IN replication_NN but_CC are_VBP defective_JJ for_IN helicase_NN activity_NN ._SENT We_PP proposed_VBD that_IN the_DT transdominance_NN exhibited_VBN by_IN these_DT mutants_NNS is_VBZ a_DT result_NN of_IN inhibition_NN of_IN HSV-1_JJ replication_NN at_IN stage_NN I_PP ,_, due_JJ to_TO lack_NN of_IN helicase_NN activity_NN ,_, and_CC inhibition_NN of_IN the_DT transition_NN between_IN stage_NN I_PP and_CC stage_VB II_NP ,_, due_JJ to_TO overexpression_NN of_IN protein_NN capable_JJ of_IN binding_VBG the_DT origin_NN ,_, as_RB proposed_VBN above_IN for_IN wild-type_NN UL9_NP ._SENT In_IN contrast_NN to_TO the_DT transdominant_JJ mutations_NNS in_IN helicase_NN motifs_NNS I_PP ,_, Ia_NP ,_, II_NP ,_, and_CC VI_NP ,_, a_DT mutation_NN in_IN motif_NN V_CD (_( G354A_NP )_) was_VBD found_VBN to_TO confer_VB a_DT potentiating_VBG phenotype_NN ._SENT When_WRB cells_NNS were_VBD cotransfected_VBN with_IN this_DT mutant_JJ and_CC wild-type_JJ infectious_JJ DNA_NN ,_, the_DT plaque_NN number_NN increased_VBD compared_VBN to_TO transfection_NN with_IN wild-type_JJ infectious_JJ DNA_NN alone_RB ._SENT Interestingly_RB ,_, no_DT stable_JJ mutant_JJ protein_NN could_MD be_VB detected_VBN in_IN the_DT transient_JJ transfection-Western_NN blot_NN assay_NN ._SENT Intrigued_VBN by_IN the_DT ability_NN of_IN an_DT apparently_RB unstable_JJ protein_NN to_TO potentiate_VB HSV-1_JJ infection_NN ,_, we_PP sought_VBD to_TO further_RBR understand_VB the_DT mechanism_NN of_IN potentiation_NN ._SENT In_IN this_DT paper_NN ,_, we_PP show_VBP that_IN the_DT ability_NN of_IN the_DT UL9_NP G234A_NP (_( motif_NN V_CD )_) mutation_NN to_TO potentiate_VB HSV-1_JJ infection_NN inversely_RB correlates_VBZ with_IN protein_NN stability_NN ._SENT The_DT overexpression_NN of_IN UL9-MV_NP is_VBZ able_JJ to_TO reduce_VB the_DT steady-state_NN wild-type_NN UL9_NP protein_NN levels_NNS and_CC override_VB its_PP$ inhibitory_JJ effects_NNS ._SENT Furthermore_RB ,_, we_PP report_VBP that_IN a_DT fragment_NN consisting_VBG of_IN the_DT N-terminal_JJ 535_CD amino_NN acids_NNS of_IN UL9_NP is_VBZ also_RB transdominant_JJ ._SENT Based_VBN on_IN the_DT genetic_JJ and_CC biochemical_JJ properties_NNS of_IN UL9_NP helicase_NN motif_NN mutants_NNS ,_, we_PP propose_VBP a_DT model_NN for_IN the_DT mechanism_NN of_IN transdominance_NN and_CC potentiation_NN ._SENT Reagents_NNS and_CC materials_NNS ._SENT |_SYM All_DT restriction_NN enzymes_NNS were_VBD purchased_VBN from_IN New_NP England_NP Biolabs_NP ._SENT The_DT pFastBac_NN vector_NN was_VBD purchased_VBN from_IN Gibco-BRL_NP ;_: the_DT pCDNA-1_JJ and_CC pCDNA-3_JJ vectors_NNS were_VBD from_IN Invitrogen_NP ._SENT Supplemented_VBN Grace_NP 's_POS medium_NN and_CC penicillin-streptomycin_NN were_VBD purchased_VBN from_IN Gibco-BRL_NP ;_: fetal_JJ calf_NN serum_NN was_VBD from_IN Gemini_NP Bioproducts_NP Inc._NP Viruses_NNS and_CC cells_NNS ._SENT |_SYM HSV-1_NP strain_NN KOS_NP was_VBD used_VBN as_IN the_DT wild-type_NN virus_NN in_IN all_DT assays_NNS ._SENT hr94_NN ,_, a_DT UL9_NP lacZ_NP insertion_NN mutant_NN ,_, was_VBD described_VBN previously_RB ._SENT Vero_NP cells_NNS (_( American_NP Type_NP Culture_NP Collection_NP )_) and_CC 2B-11_JJ ,_, a_DT Vero-derived_NP cell_NN line_NN stably_RB transfected_VBN with_IN wild-type_NP UL9_NP ,_, were_VBD maintained_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN as_RB described_VBD previously_RB ._SENT Spodoptera_NP frugiperda_NP Sf21_NP insect_NN cells_NNS were_VBD maintained_VBN in_IN serum-free_JJ medium_NN containing_VBG 0.1_CD mg_NN of_IN streptomycin_NN per_IN ml_NN and_CC 100_CD units_NNS of_IN penicillin_NN per_IN ml_NN ._SENT Escherichia_NP coli_NNS DH5alpha_NP cells_NNS were_VBD used_VBN for_IN plasmid_NP amplification_NN ._SENT DH10Bac_NP competent_JJ cells_NNS (_( Gibco-BRL_NP )_) were_VBD used_VBN for_IN bacmid_JJ packaging_NN and_CC propagation_NN ._SENT Antibodies_NNS ._SENT |_SYM Several_JJ anti-UL9_NN antibodies_NNS were_VBD used_VBN in_IN this_DT study_NN :_: R250_NP (_( a_DT kind_NN gift_NN from_IN M._NP Challberg_NP ,_, National_NP Institutes_NPS of_IN Health_NP )_) is_VBZ a_DT polyclonal_JJ antibody_NN that_WDT recognizes_VBZ the_DT C-terminal_JJ 10_CD amino_NN acids_NNS of_IN UL9_NP ;_: 17B_NP is_VBZ a_DT monoclonal_NN antibody_NN that_WDT recognizes_VBZ the_DT N-terminal_JJ 35_CD amino_NN acids_NNS of_IN UL9_NP ;_: and_CC RH7_JJ (_( a_DT kind_NN gift_NN from_IN D._NP Tenney_NP ,_, Bristol_NP Meyers_NP Squib_NP )_) was_VBD raised_VBN against_IN a_DT glutathione_NN S-transferase_NN fusion_NN with_IN the_DT UL9_NP C-terminal_NP domain_NN (_( residues_NNS 535_CD to_TO 851_CD )_) ._SENT The_DT polyclonal_JJ anti-UL6_NN antibody_NN was_VBD described_VBN previously_RB ._SENT Anti-AU1_JJ tag_NN antibody_NN was_VBD purchased_VBN from_IN Babco_NP (_( Berkeley_NP ,_, Calif._NP )_) ,_, and_CC polyclonal_JJ anti-ICP8_JJ antibody_NN was_VBD a_DT kind_NN gift_NN from_IN W._NP Ruyechan_NP ,_, State_NP University_NP of_IN New_NP York_NP ,_, Buffalo_NP ,_, N.Y._NP ._SENT Fluorescein_NN isothiocyanate-conjugated_JJ anti-mouse_NN or_CC anti-rabbit_NN immunoglobulin_NN and_CC Texas_NP red-conjugated_JJ anti-mouse_NN or_CC anti-rabbit_JJ immunoglobulin_NN antibodies_NNS were_VBD used_VBN as_IN secondary_JJ antibodies_NNS for_IN immunofluorescence_NN analysis_NN ._SENT Commercially_RB available_JJ antitubulin_NN antibody_NN (_( Sigma_NP )_) was_VBD used_VBN in_IN Western_JJ blot_NN analysis_NN to_TO monitor_VB sample_NN loading_NN ._SENT Anti-His_NN tag_NN India_NP probe_NN (_( Pierce_NP )_) was_VBD used_VBN to_TO detect_VB His-tagged_JJ UL9_JJ fusions_NNS ._SENT Plasmids_NNS ._SENT |_SYM The_DT pFastBac_JJ transfer_NN vectors_NNS were_VBD used_VBN to_TO generate_VB recombinant_JJ baculoviruses_NNS bearing_VBG the_DT C-terminal_JJ 317_CD amino_NN acids_NNS of_IN UL9_NP (_( pFastBac-UL9-CT_NN )_) and_CC the_DT N-terminal_JJ 535_CD amino_NN acids_NNS of_IN UL9_NP (_( pFastBac-UL9-NT_NN )_) ._SENT The_DT BamHI-_NP and_CC EcoRI-digested_NP PCR_NP product_NN containing_VBG the_DT C_NP terminus_NN (_( UL9-CT_NP )_) was_VBD inserted_VBN in_IN the_DT pFastBac_JJ plasmid_NN to_TO generate_VB pFastBac-UL9-CT_NN ._SENT The_DT PCR_NP product_NN was_VBD amplified_VBN by_IN stepdown_JJ PCR_NP with_IN pFastBac-UL9-WT-expressing_VBG plasmid_NN as_IN a_DT template_NN and_CC the_DT following_VBG oligonucleotides_NNS :_: BamHI-UL9Delta1-534_NP (_( 5'-GCCGAGGTGGATCCATGGATCCCGAGGCGTCGCTGCCGGCCCA-3_NP '_POS )_) and_CC 3'PCL-pFastBac_JJ (_( 5'-GATTATGATCCTCTAGTACTTCTC-3_JJ '_'' )_) ._SENT The_DT pFastBac-UL9-NT_NN plasmid_NN was_VBD generated_VBN by_IN cloning_VBG a_DT BamHI-_NP and_CC EcoRI-digested_NP PCR_NP product_NN containing_VBG UL9-NT_NP into_IN the_DT pFastBac_JJ plasmid_NN ._SENT The_DT UL9-NT_NP PCR_NP fragment_NN was_VBD amplified_VBN by_IN stepdown_JJ PCR_NP with_IN the_DT pFastBac-UL9-WT_JJ plasmid_NN as_IN a_DT template_NN and_CC the_DT following_VBG oligonucleotides_NNS :_: UL9Delta535-851-EcoRI_NP (_( 5'-GCCGAGGTGAATTCTTACTACCGGCACCGCAGCTCCCGTAGATCG-3_NP '_POS )_) and_CC 5'PCL-pFastBac_NP (_( 5'-GATTATTCATACCGTCCCACCATC-3_NP '_POS )_) ._SENT The_DT pCDNA3-UL9-WT_NN plasmid_NN ,_, expressing_VBG wild-type_NN UL9_NN under_IN the_DT control_NN of_IN a_DT cytomegalovirus_NN promoter_NN ,_, was_VBD generated_VBN by_IN inserting_VBG a_DT BamHI-EcoRI_NP fragment_NN containing_VBG the_DT wild-type_NN UL9_JJ gene_NN from_IN pFastBac-UL9-WT_NN into_IN the_DT pCDNA3_JJ vector_NN (_( Invitrogen_NP )_) ._SENT The_DT pCDNA3-UL9-MI_NP plasmid_NP ,_, carrying_VBG the_DT K87A_NP mutation_NN in_IN helicase_NN motif_NN I_PP ,_, was_VBD generated_VBN by_IN inserting_VBG a_DT BamHI-EcoRI_NP fragment_NN from_IN pCDNA1-UL9-MI_NNS into_IN the_DT pCDNA3_JJ vector_NN ._SENT The_DT pCDNA3-UL9-MV_NP plasmid_NP was_VBD generated_VBN by_IN replacing_VBG the_DT wild-type_NN UL9_JJ sequence_NN in_IN pCDNA3-UL9-WT_NN with_IN an_DT AscI-EcoRI_NP fragment_NN containing_VBG the_DT G354A_NP mutation_NN from_IN p6UL9-MV_NP ._SENT The_DT pCDNA3-UL9-MI/MV_NP double_JJ mutant_NN was_VBD generated_VBN by_IN subcloning_VBG an_DT AscI-EcoRI_NP fragment_NN containing_VBG the_DT G354A_NP mutation_NN from_IN p6UL9-MV_NP into_IN pCDNA3-UL9-MI_NP ,_, replacing_VBG the_DT corresponding_JJ wild-type_NN fragment_NN ._SENT pCDNA3-UL9_JJ NTD_NN and_CC pCDNA-UL9-CTD_NNS were_VBD generated_VBN by_IN inserting_VBG the_DT BamHI-EcoRI_NP fragment_NN from_IN pFastBac-UL9_JJ NTD_NN and_CC pFastBac-UL9-CTD_NN ,_, respectively_RB ,_, into_IN the_DT pCDNA3_JJ vector_NN ._SENT The_DT pCDNA3-UL9Delta322-851_NN ,_, pCDNA3-UL9Delta355-851-MV_NP ,_, and_CC pCDNA3-UL9Delta450-851_JJ plasmids_NNS were_VBD generated_VBN by_IN inserting_VBG the_DT AscI-_NP and_CC EcoRI-digested_NP PCR_NP fragments_VBZ containing_VBG the_DT corresponding_JJ truncations_NNS into_IN pCDNA3-UL9-WT_NN ,_, replacing_VBG the_DT wild-type_NN fragment_NN ._SENT All_DT PCR_NP fragments_NNS were_VBD generated_VBN by_IN stepdown_JJ PCR_NP with_IN the_DT pFastBac-UL9-WT_JJ plasmid_NN as_IN the_DT template_NN and_CC OligoI_NP (_( 5'-GCGGAGTCGGGAGATCCTCTGGGG-3_NP '_POS )_) as_IN the_DT upstream_JJ primer_NN ._SENT The_DT pCDNA3-UL9Delta450-851-MV_NP truncation_NN was_VBD generated_VBN with_IN the_DT same_JJ procedure_NN except_IN that_WDT the_DT p6UL9-MV_NP plasmid_NP was_VBD used_VBN as_IN a_DT template_NN in_IN the_DT PCR_NP ._SENT The_DT specific_JJ downstream_JJ oligonucleotides_NNS used_VBN to_TO generate_VB the_DT above_JJ truncations_NNS were_VBD UL9Delta322-851_JJ (_( 5'-GCCGAGGTGAATTCTCATTAGTCCGTAAACTGACGGCAGAACCGGGCCAC-3_NP '_POS )_) ,_, UL9Delta355-851-MV_NP (_( 5'-GCCGAGGTGAATTCTCATTAGGCCACCGTTACGACCGTCGTGTATATAACCACGCG-3_NP '_POS )_) ,_, and_CC UL9Delta450-851_NP (_( 5'-GCCGAGGTGAATTCTCATTAGCATGCCGACGCGTCACAGCGCCCCTTGAACC-3_NP '_POS )_) ._SENT The_DT pUL9Eco_NP plasmid_NP ,_, cont-aining_VBG UL9_NP under_IN the_DT control_NN of_IN its_PP$ natural_JJ promoter_NN ,_, was_VBD generously_RB provided_VBN by_IN P._NP Schaffer_NP (_( University_NP of_IN Pennsylvania_NP School_NP of_IN Medicine_NP )_) ._SENT J._NP Nellissery_NP kindly_RB provided_VBD the_DT pCDNA3-UL6_JJ plasmid_NN ._SENT The_DT p6UL9-119b_NN plasmid_NN ,_, containing_VBG the_DT UL9_JJ gene_NN under_IN the_DT control_NN of_IN the_DT ICP6_NP promoter_NN ,_, was_VBD described_VBN previously_RB ._SENT The_DT pCDNA3-UL9-NT-AU1_JJ plasmid_NN was_VBD generated_VBN by_IN subcloning_VBG an_DT AscI-_NP and_CC NotI-digested_NP PCR_NP product_NN into_IN pCDNA3-UL9-WT_NN ,_, replacing_VBG the_DT corresponding_JJ wild-type_NN fragment_NN ._SENT The_DT PCR_NP product_NN was_VBD generated_VBN by_IN stepdown_JJ PCR_NP with_IN the_DT pFastBac-UL9-WT_JJ plasmid_NN as_IN a_DT template_NN ,_, OligoI_NP (_( 5'-GCGGAGTCGGGAGATCCTCTGGGG-3_NP '_POS )_) as_IN the_DT upstream_JJ primer_NN ,_, and_CC UL9-NT-AU1_NP (_( 5'-GCCGGCTTCTGCGGCCGCTCACTATATATAGCGATACGTATCATCCCGGCACCGCAGCTCCCGTATG-3_NP '_POS )_) as_IN the_DT downstream_JJ primer_NN ._SENT The_DT nucleotide_NN sequence_NN encoding_VBG the_DT AU1_JJ tag_NN is_VBZ underlined_VBN ._SENT The_DT cloning_VBG procedure_NN resulted_VBN in_IN the_DT addition_NN of_IN the_DT AU1_JJ tag_NN (_( DTYRYI_NP )_) at_IN the_DT C_NP terminus_NN of_IN UL9-NT_NP ._SENT The_DT pCDNA3-AU1-UL9_JJ plasmid_NN was_VBD created_VBN by_IN inserting_VBG a_DT BamHI-EcoRI_NP fragment_NN containing_VBG the_DT wild-type_NN UL9_JJ gene_NN into_IN the_DT pCDNA3-AU1_JJ vector_NN ,_, resulting_VBG in_IN the_DT addition_NN of_IN an_DT AU1_JJ tag_NN at_IN the_DT N_NP terminus_NN of_IN UL9_NP ._SENT The_DT pCDNA3-AU1_JJ vector_NN was_VBD generated_VBN by_IN ligation_NN of_IN an_DT AU1-containing_NP linker_NN in_IN the_DT polycloning_VBG site_NN via_IN the_DT HindIII_NP and_CC BamHI_NP sites_NNS ._SENT The_DT AU1-containing_NP linker_NN was_VBD created_VBN by_IN annealing_VBG the_DT BM-HB-AU1-T_NP (_( 5'-AGCTTACCATGGATACGTATCGCTACATAG-3_NP '_POS )_) and_CC BM-HB-AU1-B_NP (_( 5'-GATCCTATGTAGCGATACGTATCCATGGTA-3_NP '_POS )_) oligonucleotides_NNS ._SENT The_DT nucleotide_NN sequence_NN encoding_VBG the_DT AU1_JJ tag_NN is_VBZ underlined_VBN ._SENT Generation_NN of_IN recombinant_JJ baculoviruses_NNS expressing_VBG UL9_JJ variants_NNS ._SENT |_SYM Recombinant_NP baculoviruses_NNS (_( Autographa_NP californica_NP nuclear_JJ polyhedrosis_NN baculoviruses_NNS )_) expressing_VBG wild-type_NN or_CC mutant_JJ UL9_NP variants_NNS were_VBD generated_VBN with_IN the_DT pFastBac_NN (_( Gibco-BRL_NP )_) system_NN according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Cell_NN lysates_NNS ._SENT |_SYM Two_NP types_NNS of_IN mammalian_JJ cell_NN lysates_NNS were_VBD used_VBN in_IN this_DT study_NN ._SENT Regular_JJ cell_NN lysates_NNS were_VBD obtained_VBN from_IN one_CD 60-mm2_JJ plate_NN which_WDT was_VBD washed_VBN with_IN phosphate-buffered_JJ saline_NN containing_VBG a_DT Sigma_NP protease_NN inhibitor_NN cocktail_NN ,_, harvested_VBN ,_, and_CC resuspended_VBD in_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN (_( SDS-PAGE_NP )_) loading_NN buffer_NN ,_, resulting_VBG in_IN a_DT total_NN of_IN 300_CD mul_NN of_IN lysate_NNS ._SENT The_DT lysates_NNS were_VBD boiled_VBN and_CC analyzed_VBN by_IN Western_JJ blot_NN analysis_NN ._SENT Concentrated_JJ cell_NN lysates_NNS were_VBD prepared_VBN from_IN one_CD 60-mm2_JJ plate_NN ,_, which_WDT was_VBD harvested_VBN and_CC resuspended_VBN in_IN SDS-PAGE_NP loading_NN buffer_NN ,_, resulting_VBG in_IN a_DT total_NN of_IN 60_CD mul_NN of_IN five-fold-concentrated_JJ lysate_NNS ._SENT The_DT samples_NNS were_VBD cup-sonicated_VBN twice_RB (_( Sonicator_NP Ultra_NP Processor_NP XL_NP ;_: Misonix_NP ,_, Inc._NP ;_: power_NN setting_VBG 9_CD for_IN 1_CD min_NN )_) ,_, boiled_VBD ,_, and_CC analyzed_VBD ._SENT Transient_JJ transfection-complementation_NN assay_NN ._SENT |_SYM The_DT transient_JJ transfection-complementation_NN assay_NN was_VBD performed_VBN as_IN described_VBN previously_RB ._SENT Each_DT experiment_NN was_VBD repeated_VBN three_CD times_NNS ,_, and_CC the_DT mean_JJ complementation_NN index_NN was_VBD calculated_VBN ._SENT Plaque_NN reduction_NN assay_NN ._SENT |_SYM The_DT plaque_NN reduction_NN assay_NN was_VBD performed_VBN as_IN described_VBN previously_RB ._SENT In_IN brief_NN ,_, Vero_NP cells_NNS in_IN 60-mm2_JJ plates_NNS at_IN 50_CD %_NN confluence_NN were_VBD cotransfected_VBN with_IN wild-type_JJ HSV-1_JJ infectious_JJ DNA_NN (_( strain_NN KOS_NP )_) and_CC the_DT plasmid_NN of_IN interest_NN (_( at_IN a_DT ratio_NN of_IN 1:10_CD )_) with_IN Lipofectamine_NP Plus_NP (_( Gibco_NP )_) ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS recommendations_NNS ._SENT The_DT plates_NNS were_VBD overlaid_VBN with_IN methylcellulose_NN and_CC incubated_VBN until_IN plaques_NNS were_VBD observed_VBN ._SENT Plaques_NNS were_VBD stained_VBN with_IN crystal_NN violet_NN and_CC counted_VBN ._SENT Each_DT experiment_NN was_VBD performed_VBN three_CD times_NNS ,_, and_CC the_DT mean_JJ number_NN of_IN plaques_NNS and_CC the_DT standard_JJ deviation_NN were_VBD calculated_VBN ._SENT Immunofluorescent_JJ microscopy_NN ._SENT |_SYM Vero_NP cells_NNS were_VBD transfected_VBN with_IN 2_CD mug_NN of_IN the_DT plasmid_NN of_IN interest_NN with_IN Lipofectamine_NP Plus_NP (_( Gibco_NP )_) and_CC processed_VBN for_IN immunofluorescence_NN 18_CD h_NN posttransfection_NN ._SENT The_DT transfected_JJ cells_NNS were_VBD fixed_VBN ,_, permeabilized_VBN ,_, and_CC stained_VBD as_RB described_VBN previously_RB except_IN that_IN all_DT procedures_NNS were_VBD performed_VBN at_IN room_NN temperature_NN and_CC phosphate-buffered_JJ saline_NN was_VBD supplemented_VBN with_IN 0.1_CD mM_NP CaCl2_NP and_CC 1_CD mM_NP MgCl2_NP to_TO reduce_VB cell_NN detachment_NN ._SENT The_DT primary_JJ antibodies_NNS were_VBD used_VBN at_IN the_DT following_VBG dilutions_NNS :_: 17B_JJ ,_, undiluted_JJ ;_: RH7_JJ ,_, 1:100_CD dilution_NN ;_: anti-ICP8_NP ,_, 1:400_CD dilution_NN ;_: anti-AU1_JJ ,_, 1:500_CD dilution_NN ._SENT The_DT secondary_JJ antibodies_NNS were_VBD used_VBN at_IN a_DT dilution_NN of_IN 1:200_CD ._SENT Images_NNS were_VBD taken_VBN with_IN an_DT Olympus_NP BX60_NP microscope_NN (_( at_IN 100x_NP magnification_NN )_) equipped_VBN with_IN a_DT Hamamatsu_NP Orca_NP digital_JJ camera_NN (_( model_NN C4742-95_NP )_) and_CC Open_NP Lab_NP software_NN (_( Improvisions_NNS )_) ._SENT Images_NNS were_VBD processed_VBN and_CC arranged_VBN with_IN Adobe_NP Photoshop_NP 6.0_CD and_CC Adobe_NP Illustrator_NP 7.0_CD software_NN ._SENT The_DT UL9_NP helicase_NN motif_NN mutants_NNS were_VBD classified_VBN as_IN transdominant_NN or_CC potentiating_VBG based_VBN on_IN a_DT plaque_NN reduction_NN assay_NN in_IN which_WDT cells_NNS were_VBD cotransfected_VBN with_IN wild-type_JJ infectious_JJ DNA_NN and_CC an_DT excess_NN of_IN UL9-encoding_NP plasmid_NP ._SENT The_DT number_NN of_IN plaques_NNS observed_VBN in_IN cells_NNS transfected_VBN with_IN infectious_JJ DNA_NN only_RB was_VBD normalized_VBN to_TO 100_CD ._SENT Overexpression_NN of_IN wild-type_NP UL9_NP slightly_RB reduced_VBD the_DT number_NN of_IN plaques_NNS in_IN this_DT assay_NN (_( 60_CD compared_VBN to_TO 100_CD )_) ;_: therefore_RB ,_, wild-type_NP UL9_NP is_VBZ considered_VBN inhibitory_JJ ._SENT Mutants_NNS whose_WP$ overexpression_NN resulted_VBD in_IN significant_JJ reduction_NN of_IN the_DT plaque_NN number_NN were_VBD classified_VBN as_IN transdominant_NN ._SENT For_IN instance_NN ,_, in_IN cells_NNS transfected_VBN with_IN motif_NN I_PP ,_, Ia_NP ,_, II_NP ,_, and_CC VI_CD mutants_NNS ,_, the_DT number_NN of_IN plaques_NNS dropped_VBD to_TO 10_CD to_TO 15_CD ._SENT In_IN contrast_NN ,_, mutants_NNS whose_WP$ overexpression_NN led_VBD to_TO increased_VBN plaque_NN number_NN were_VBD classified_VBN as_IN potentiating_VBG ._SENT In_IN cells_NNS transfected_VBN with_IN the_DT motif_NN V_CD mutant_NN ,_, the_DT plaque_NN number_NN increased_VBD to_TO 180_CD ._SENT It_PP was_VBD shown_VBN previously_RB that_IN the_DT motif_NN V_NN mutant_JJ protein_NN was_VBD undetectable_JJ in_IN mammalian_JJ cells_NNS transiently_RB transfected_VBN with_IN a_DT mammalian_JJ expression_NN vector_NN under_IN the_DT control_NN of_IN the_DT ICP6_NP promoter_NN ._SENT No_DT protein_NN could_MD be_VB detected_VBN in_IN immunoblots_NNS of_IN cell_NN lysates_NNS from_IN UL9-MV-transfected_JJ cells_NNS with_IN any_DT of_IN the_DT available_JJ anti-UL9_JJ antibodies_NNS (_( 17B_NP ,_, raised_VBN against_IN the_DT extreme_JJ N_NP terminus_NN ;_: R250_NP ,_, recognizing_VBG the_DT extreme_JJ C_NP terminus_NN ;_: or_CC RH7_JJ ,_, raised_VBN against_IN the_DT whole_JJ C-terminal_JJ domain_NN )_) ._SENT In_IN addition_NN ,_, a_DT mutant_NN carrying_VBG the_DT motif_NN V_CD mutation_NN and_CC the_DT OB_NP mutation_NN (_( a_DT 4-amino-acid_JJ insertion_NN after_IN residue_NN 591_CD in_IN the_DT C-terminal_JJ domain_NN of_IN UL9_NP that_WDT abolishes_VBZ the_DT origin-specific_JJ DNA_NN function_NN )_) was_VBD even_RB more_RBR potentiating_VBG than_IN the_DT motif_NN V_NN mutant_NN alone_RB ;_: the_DT number_NN of_IN plaques_NNS in_IN this_DT case_NN was_VBD increased_VBN to_TO 220_CD ._SENT These_DT results_NNS indicated_VBD that_IN the_DT motif_NN V_NN mutant_NN was_VBD capable_JJ of_IN influencing_VBG the_DT outcome_NN of_IN a_DT viral_JJ infection_NN and_CC thus_RB must_MD be_VB expressed_VBN ,_, at_IN least_JJS transiently_RB ._SENT N-terminal_JJ fragment(s)_NN but_CC not_RB full-length_JJ UL9-MV_NP protein_NN can_MD be_VB detected_VBN in_IN heterologous_JJ expression_NN systems_NNS ._SENT |_SYM In_IN order_NN to_TO determine_VB if_IN the_DT motif_NN V_NN mutant_JJ protein_NN could_MD be_VB detected_VBN in_IN heterologous_JJ expression_NN systems_NNS ,_, UL9-MV_NP was_VBD expressed_VBN in_IN insect_NN cells_NNS with_IN recombinant_JJ baculoviruses_NNS ._SENT Cell_NN lysates_NNS of_IN insect_NN cells_NNS infected_VBN with_IN the_DT recombinant_JJ virus_NN bearing_NN wild-type_NN UL9_NP or_CC the_DT UL9-MV_NP mutant_NN were_VBD subjected_VBN to_TO Western_JJ blot_NN analysis_NN with_IN antibodies_NNS which_WDT recognize_VBP the_DT extreme_JJ N_NP terminus_NN (_( 17B_JJ )_) or_CC the_DT extreme_JJ C_NP terminus_NN (_( R250_NP )_) of_IN the_DT UL9_NP protein_NN ._SENT Both_DT antibodies_NNS detected_VBD full-length_JJ wild-type_NN UL9_NN protein_NN (_( Fig._NN ,_, lanes_NNS 2_CD and_CC 5_CD ,_, respectively_RB )_) ._SENT Consistent_JJ with_IN our_PP$ previous_JJ findings_NNS in_IN mammalian_JJ cells_NNS ,_, no_DT full-length_JJ UL9-MV_NP protein_NN was_VBD observed_VBN with_IN 17B_NP or_CC R250_NP antibodies_NNS (_( Fig._NN ,_, lanes_NNS 3_CD and_CC 6_CD ,_, respectively_RB )_) ._SENT Surprisingly_RB ,_, the_DT 17B_JJ antibody_NN was_VBD able_JJ to_TO detect_VB two_CD fragments_NNS of_IN approximately_RB 38_CD kDa_NNS (_( marked_VBN with_IN an_DT arrowhead_NN )_) and_CC 30_CD kDa_NNS (_( marked_VBN with_IN two_CD arrowheads_NNS )_) ._SENT No_DT fragments_NNS were_VBD detected_VBN with_IN the_DT anti-C_NN terminus_NN antibody_NN (_( R250_NP )_) (_( Fig._NN ,_, lane_NN 6_CD )_) ._SENT The_DT relative_JJ amount_NN of_IN the_DT 30-kDa_JJ fragment_NN varied_VBN between_IN different_JJ sample_NN preparations_NNS ,_, suggesting_VBG that_IN it_PP may_MD be_VB a_DT degradation_NN product_NN of_IN the_DT 38-kDa_JJ fragment_NN ._SENT We_PP next_RB asked_VBD whether_IN the_DT appearance_NN of_IN the_DT N-terminal_JJ fragments_NNS in_IN insect_NN cells_NNS but_CC not_RB in_IN mammalian_JJ cells_NNS reflects_VBZ different_JJ expression_NN levels_NNS and/or_CC stability_NN in_IN these_DT two_CD types_NNS of_IN cells_NNS ._SENT In_IN order_NN to_TO determine_VB if_IN our_PP$ previous_JJ failure_NN to_TO detect_VB UL9-MV_NP was_VBD due_JJ to_TO expression_NN levels_NNS ,_, we_PP cloned_VBD the_DT UL9-MV_NP mutant_NN in_IN a_DT mammalian_JJ expression_NN vector_NN (_( pCDNA3_NP ;_: Invitrogen_NP )_) under_IN the_DT control_NN of_IN the_DT cytomegalovirus_NN immediate-early_JJ promoter_NN ,_, a_DT strong_JJ constitutive_JJ promoter_NN ._SENT Vero_NP cells_NNS were_VBD transfected_VBN with_IN the_DT pCDNA3-UL9-MV_NP plasmid_NP ,_, and_CC the_DT cell_NN lysates_NNS were_VBD assayed_VBN for_IN the_DT presence_NN of_IN UL9-MV_NP protein_NN or_CC UL9-MV_NP fragments_NNS ._SENT As_IN previously_RB seen_VBN with_IN vectors_NNS with_IN the_DT ICP6_NP promoter_NN ,_, no_DT protein_NN species_NNS were_VBD detected_VBN with_IN any_DT of_IN the_DT anti-UL9_JJ antibodies_NNS (_( data_NNS not_RB shown_VBN )_) ,_, but_CC when_WRB concentrated_JJ lysates_NNS of_IN cells_NNS transfected_VBN with_IN pCDNA3-UL9-MV_NP were_VBD prepared_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ,_, the_DT 17B_JJ antibody_NN detected_VBD an_DT N-terminal_JJ fragment_NN with_IN an_DT apparent_JJ mobility_NN of_IN approximately_RB 38_CD kDa_NN (_( Fig._NN ,_, lane_NN 4_CD )_) ._SENT No_DT specific_JJ bands_NNS were_VBD detected_VBN with_IN the_DT R250_NP antibody_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Thus_RB ,_, we_PP have_VBP demonstrated_VBN that_IN in_IN both_DT insect_NN and_CC mammalian_JJ expression_NN systems_NNS ,_, no_DT full-length_JJ UL9-MV_NP protein_NN is_VBZ detectable_JJ ;_: instead_RB ,_, an_DT N-terminal_JJ fragment_NN with_IN similar_JJ if_IN not_RB identical_JJ mobility_NN was_VBD observed_VBN in_IN both_DT cell_NN types_NNS ._SENT Interestingly_RB ,_, a_DT fragment_NN with_IN the_DT same_JJ mobility_NN was_VBD observed_VBN when_WRB UL9-MV_NP was_VBD cloned_VBN with_IN an_DT N-terminal_NP His_PP$ tag_NN and_CC expressed_VBN in_IN E._NP coli_NNS (_( Fig._NN ,_, lane_NN 6_CD )_) ._SENT The_DT apparent_JJ molecular_JJ mass_NN of_IN the_DT N-terminal_NP UL9-MV_NP fragment_NN was_VBD determined_VBN to_TO be_VB approximately_RB 38_CD kDa_NN ,_, as_RB judged_VBN by_IN Coomassie-stained_NP SDS-PAGE_NP gels_VBZ with_IN Benchmark_NP (_( Invitrogen_NP )_) or_CC broad_JJ range_NN (_( New_NP England_NP Biolab_NP )_) molecular_JJ weight_NN protein_NN standards_NNS ._SENT Thus_RB ,_, it_PP appears_VBZ that_IN a_DT similar_JJ 38-kDa_JJ band_NN is_VBZ generated_VBN by_IN expression_NN of_IN the_DT motif_NN V_CD mutant_NN in_IN all_DT three_CD expression_NN systems_NNS ._SENT We_PP propose_VBP that_IN the_DT G354A_NP mutation_NN results_NNS in_IN a_DT conformational_JJ change(s)_NN in_IN the_DT mutant_JJ protein_NN leading_VBG to_TO the_DT exposure_NN of_IN a_DT normally_RB buried_VBN protease_NN cleavage_NN site(s_NNS )_) ._SENT The_DT difficulties_NNS that_IN we_PP encountered_VBD in_IN detecting_VBG the_DT 38-kDa_JJ fragment_NN at_IN first_JJ may_MD indicate_VB that_IN some_DT of_IN the_DT mutant_JJ MV_NP protein_NN is_VBZ degraded_VBN completely_RB ._SENT It_PP is_VBZ not_RB clear_JJ whether_IN the_DT observed_JJ 38-kDa_JJ fragment_NN is_VBZ a_DT result_NN of_IN cleavage_NN by_IN a_DT protease_NN present_NN in_IN all_DT three_CD cell_NN types_NNS or_CC whether_IN this_DT fragment_NN represents_VBZ the_DT minimal_JJ stably_RB folded_VBN fragment_NN and_CC is_VBZ not_RB the_DT result_NN of_IN the_DT initial_JJ cleavage_NN event_NN ._SENT Potentiation_NP is_VBZ not_RB due_JJ to_TO absence_NN of_IN the_DT transdominant_JJ origin-binding_NN domain_NN of_IN UL9_NP ._SENT |_SYM The_DT UL9_NP C-terminal_NP domain_NN (_( UL9_NP CTD_NP )_) ,_, encompassing_VBG residues_NNS 536_CD to_TO 851_CD ,_, is_VBZ transdominant_JJ in_IN the_DT context_NN of_IN the_DT plaque_NN reduction_NN assay_NN and_CC in_IN coinfections_NNS of_IN wild-type_NN HSV-1_JJ and_CC recombinant_JJ HSV-1_NP expressing_VBG the_DT UL9_NP CTD_NP ._SENT The_DT transdominant_JJ effect_NN of_IN the_DT UL9_NP CTD_NP is_VBZ abolished_VBN if_IN a_DT mutation_NN disrupting_VBG the_DT origin-binding_NN function_NN is_VBZ introduced_VBN ._SENT Since_IN the_DT C_NP terminus_NN of_IN UL9_NP is_VBZ clearly_RB transdominant_JJ and_CC since_IN no_DT stable_JJ C-terminal_JJ fragments_NNS were_VBD detected_VBN when_WRB the_DT potentiating_VBG mutant_JJ UL9-MV_NP was_VBD expressed_VBN ,_, we_PP wanted_VBD to_TO rule_VB out_RP the_DT formal_JJ possibility_NN that_IN the_DT absence_NN of_IN the_DT C-terminal_JJ domain_NN is_VBZ responsible_JJ for_IN potentiation_NN ._SENT We_PP hypothesized_VBD that_IN the_DT potentiating_VBG phenotype_NN may_MD simply_RB be_VB a_DT result_NN of_IN the_DT absence_NN of_IN the_DT transdominant_JJ C-terminal_JJ portion_NN of_IN UL9_NP ._SENT If_IN this_DT hypothesis_NN is_VBZ correct_JJ ,_, it_PP would_MD be_VB expected_VBN that_IN the_DT N-terminal_JJ portion_NN of_IN UL9_NP (_( UL9_NP NTD_NP )_) ,_, lacking_VBG the_DT transdominant_JJ origin-binding_NN domain_NN ,_, would_MD be_VB potentiating_VBG ._SENT In_IN order_NN to_TO test_VB this_DT hypothesis_NN ,_, a_DT construct_NN expressing_VBG the_DT UL9_NP NTD_NP was_VBD generated_VBN and_CC tested_VBN in_IN the_DT plaque_NN reduction_NN assay_NN ._SENT Figure_NN shows_VBZ that_IN the_DT UL9_NP NTD_NN was_VBD transdominant_JJ rather_RB than_IN potentiating_VBG ._SENT Interestingly_RB ,_, the_DT UL9_NP NTD_NN protein_NN was_VBD not_RB detectable_JJ by_IN Western_JJ blot_NN analysis_NN with_IN the_DT 17B_JJ antibody_NN when_WRB used_VBN to_TO transfect_VB mammalian_JJ cells_NNS ,_, even_RB if_IN concentrated_JJ cell_NN lysates_NNS were_VBD prepared_VBN ,_, suggesting_VBG that_IN the_DT UL9_NP NTD_NN is_VBZ unstable_JJ ._SENT This_DT is_VBZ consistent_JJ with_IN previous_JJ observations_NNS from_IN the_DT baculovirus_NN expression_NN system_NN ._SENT It_PP should_MD be_VB noted_VBN that_IN when_WRB much_JJ larger_JJR amounts_NNS of_IN plasmid_NP DNA_NP were_VBD used_VBN for_IN transfection_NN ,_, the_DT UL9_NP NTD_NN could_MD be_VB detected_VBN but_CC only_RB at_IN very_RB low_JJ levels_NNS (_( see_VB below_IN )_) ._SENT In_IN summary_NN ,_, the_DT transdominant_JJ phenotype_NN of_IN UL9_NP NTD_NP rules_NNS out_IN the_DT possibility_NN that_IN potentiation_NN is_VBZ a_DT result_NN of_IN the_DT absence_NN of_IN the_DT UL9_NP CTD_NP ._SENT Level_NN of_IN transdominance_NN of_IN UL9_NP NTD_NP correlates_VBZ with_IN its_PP$ stability_NN and/or_CC steady-state_NN protein_NN levels_NNS in_IN the_DT cell_NN ._SENT |_SYM Since_IN the_DT UL9_NP NTD_NN is_VBZ unstable_JJ by_IN itself_PP while_IN full-length_JJ UL9_NN is_VBZ stable_JJ ,_, we_PP reasoned_VBD that_IN the_DT addition_NN of_IN a_DT tag_NN at_IN the_DT C_NP terminus_NN of_IN the_DT UL9_NP NTD_NP might_MD improve_VB its_PP$ stability_NN ._SENT An_DT AU1_NP tag_NN was_VBD added_VBN at_IN the_DT C_NP terminus_NN of_IN the_DT UL9_NP NTD_NN after_IN residue_NN 534_CD ,_, resulting_VBG in_IN UL9_NP NTD-AU1_NP ._SENT When_WRB mammalian_JJ cells_NNS were_VBD transfected_VBN with_IN this_DT construct_NN ,_, the_DT tagged_VBN version_NN of_IN the_DT N_NP terminus_NN (_( UL9_NP NTD-AU1_NP )_) was_VBD readily_RB detected_VBN in_IN Western_JJ blots_NNS with_IN the_DT 17B_JJ antibody_NN as_IN well_RB as_RB with_IN the_DT anti-AU1_JJ antibody_NN (_( data_NNS not_RB shown_VBN )_) ._SENT When_WRB UL9_NP NTD-AU1_NP was_VBD tested_VBN in_IN the_DT plaque_NN reduction_NN assay_NN ,_, it_PP was_VBD found_VBN to_TO be_VB even_RB more_JJR transdominant_NN than_IN the_DT UL9_NP NTD_NN ._SENT Transfection_NN experiments_NNS with_IN increasing_VBG amounts_NNS of_IN plasmid_NP DNA_NP demonstrated_VBD significant_JJ differences_NNS in_IN the_DT steady-state_NN levels_NNS of_IN UL9_NP NTD_NP and_CC UL9_NP NTD-AU1_NP ._SENT Whereas_IN UL9_NP NTD-AU1_NP was_VBD readily_RB observed_VBN when_WRB 2_CD mug_NN of_IN plasmid_NP DNA_NP was_VBD used_VBN for_IN transfection_NN ,_, UL9_NP NTD_NP was_VBD hardly_RB detectable_JJ when_WRB 7.5_CD mug_NN of_IN plasmid_NP DNA_NP was_VBD used_VBN ._SENT Although_IN it_PP is_VBZ possible_JJ that_IN the_DT lower_JJR steady-state_NN protein_NN levels_NNS of_IN UL9_NP NTD_NP are_VBP due_JJ to_TO lower_JJR expression_NN levels_NNS ,_, we_PP consider_VBP it_PP unlikely_JJ because_IN both_DT pUL9-NTD-AU1_NN and_CC pUL9-UL9-NTD_NNS were_VBD expressed_VBN from_IN the_DT same_JJ promoter_NN ._SENT We_PP therefore_RB favor_VBP a_DT scenario_NN in_IN which_WDT the_DT low_JJ steady-state_NN levels_NNS of_IN the_DT UL9_NP NTD_NP are_VBP due_JJ to_TO inherent_JJ instability_NN of_IN the_DT N-terminal_JJ fragment_NN of_IN UL9_NP ._SENT Thus_RB ,_, the_DT AU1_NP tag_NN appears_VBZ to_TO increase_VB the_DT stability_NN of_IN the_DT N-terminal_JJ domain_NN of_IN UL9_NP ._SENT In_IN summary_NN ,_, we_PP have_VBP demonstrated_VBN that_IN the_DT potentiation_NN phenotype_NN of_IN UL9-MV_NP is_VBZ not_RB due_JJ to_TO the_DT absence_NN of_IN the_DT C-terminal_JJ origin-binding_NN domain_NN of_IN UL9_NP ._SENT Furthermore_RB ,_, the_DT UL9_NP NTD_NN by_IN itself_PP is_VBZ transdominant_JJ ,_, and_CC its_PP$ level_NN of_IN transdominance_NN correlates_NNS with_IN stability_NN and/or_CC steady-state_NN protein_NN levels_NNS in_IN the_DT cell_NN ._SENT The_DT potentiation_NN phenotype_NN of_IN UL9-MV_NP does_VBZ not_RB depend_VB on_IN the_DT helicase_JJ activity_NN of_IN UL9_NP ._SENT |_SYM In_IN order_NN to_TO test_VB whether_IN the_DT helicase_JJ activity_NN of_IN UL9_NP is_VBZ essential_JJ for_IN the_DT potentiating_VBG phenotype_NN of_IN UL9-MV_NP ,_, a_DT double_JJ mutant_NN ,_, UL9-MI/MV_NP ,_, carrying_VBG the_DT K87A_NP mutation_NN in_IN helicase_NN motif_NN I_PP (_( Walker_NP box_NN A_NP )_) was_VBD engineered_VBN ._SENT The_DT K87A_NP mutation_NN abolishes_VBZ the_DT ATPase_NN and_CC helicase_NN activities_NNS of_IN UL9_NP ._SENT The_DT UL9-MI_NP mutant_NN was_VBD previously_RB shown_VBN to_TO be_VB transdominant_JJ in_IN the_DT context_NN of_IN the_DT plaque_NN reduction_NN assay_NN ._SENT The_DT double_JJ mutant_JJ UL9-MI/MV_NP was_VBD found_VBN to_TO be_VB potentiating_VBG ,_, resulting_VBG in_IN approximately_RB the_DT same_JJ level_NN of_IN stimulation_NN of_IN viral_JJ plaque_NN formation_NN as_IN UL9-MV_NP by_IN itself_PP (_( data_NNS not_RB shown_VBN )_) ._SENT Thus_RB ,_, the_DT addition_NN of_IN the_DT MI_NP mutation_NN does_VBZ not_RB affect_VB the_DT potentiation_NN phenotype_NN of_IN UL9-MV_NP ,_, indicating_VBG that_IN potentiation_NN does_VBZ not_RB rely_VB on_IN the_DT helicase_JJ activity_NN of_IN UL9_NP ._SENT Presence_NN of_IN the_DT MV_NP (_( G354A_NP )_) mutation_NN by_IN itself_PP is_VBZ not_RB sufficient_JJ for_IN potentiation_NN ._SENT |_SYM As_RB described_VBN above_RB ,_, UL9-MV_NP potentiation_NN is_VBZ not_RB simply_RB a_DT result_NN of_IN the_DT absence_NN of_IN the_DT transdominant_JJ CTD_NN of_IN UL9_NP and_CC is_VBZ independent_JJ of_IN the_DT helicase_JJ activity_NN of_IN the_DT protein_NN ._SENT Therefore_RB ,_, the_DT potentiation_NN is_VBZ most_RBS likely_JJ a_DT property_NN of_IN the_DT G354A_NP mutation_NN itself_PP ._SENT In_IN order_NN to_TO investigate_VB this_DT hypothesis_NN ,_, several_JJ UL9_NP truncations_NNS were_VBD engineered_VBN :_: UL9-Delta322-851_NP ,_, which_WDT ends_VBZ 22_CD amino_NN acids_NNS upstream_RB of_IN the_DT G354A_NP mutation_NN ;_: UL9-Delta355-851-MV_NP ,_, which_WDT ends_VBZ immediately_RB after_IN the_DT MV_NP mutation_NN G354A_NP and_CC corresponds_VBZ to_TO a_DT protein_NN fragment_NN with_IN predicted_VBN molecular_JJ weight_NN close_NN to_TO the_DT experimentally_RB determined_VBN size_NN of_IN the_DT UL9-MV_NP fragment_NN observed_VBD in_IN mammalian_NN ,_, insect_NN ,_, and_CC bacterial_JJ cells_NNS (_( Fig._NN and_CC Fig._NN )_) ;_: UL9-Delta450-851_NP ,_, which_WDT ends_VBZ shortly_RB after_IN the_DT last_JJ helicase_NN motif_NN of_IN UL9_NP and_CC contains_VBZ wild-type_NN sequence_NN ;_: and_CC UL9-Delta450-851-MV_NP ,_, which_WDT ends_VBZ shortly_RB after_IN the_DT last_JJ helicase_NN motif_NN and_CC contains_VBZ the_DT MV_NP mutation_NN (_( G354A_NP )_) ._SENT All_PDT the_DT mutants_NNS except_IN UL9-Delta450-851-MV_NP were_VBD found_VBN to_TO express_VB proteins_NNS of_IN the_DT predicted_VBN sizes_NNS ._SENT Interestingly_RB ,_, the_DT UL9-Delta450-851-MV_NP truncation_NN produced_VBD a_DT 38-kDa_JJ fragment_NN comparable_JJ to_TO the_DT fragment_NN seen_VBN with_IN full-length_JJ UL9-MV_NP ._SENT In_IN the_DT plaque_NN reduction_NN assay_NN ,_, all_DT truncations_NNS except_IN UL9-Delta450-851-MV_NP were_VBD found_VBN to_TO be_VB transdominant_JJ ._SENT UL9-Delta450-851-MV_NP was_VBD potentiating_VBG ,_, and_CC the_DT level_NN of_IN potentiation_NN was_VBD comparable_JJ to_TO that_DT seen_VBN with_IN UL9-MV_NP itself_PP ._SENT From_IN these_DT experiments_NNS ,_, it_PP appears_VBZ that_IN there_EX is_VBZ a_DT trend_NN correlating_VBG the_DT potentiation_NN phenotype_NN in_IN the_DT plaque_NN reduction_NN assay_NN with_IN the_DT ability_NN of_IN UL9_NP variants_NNS to_TO be_VB processed_VBN or_CC degraded_VBN to_TO the_DT 38-kDa_JJ N-terminal_JJ fragment_NN ._SENT Our_PP$ results_NNS show_VBP that_IN the_DT presence_NN of_IN the_DT MV_NP mutation_NN by_IN itself_PP is_VBZ not_RB sufficient_JJ to_TO confer_VB potentiation_NN ,_, as_RB seen_VBN from_IN the_DT transdominant_JJ phenotype_NN of_IN the_DT UL9-Delta355-851-MV_NP truncation_NN ._SENT If_IN the_DT G354A_NP mutation_NN was_VBD sufficient_JJ for_IN potentiation_NN ,_, then_RB this_DT truncation_NN would_MD be_VB expected_VBN to_TO be_VB potentiating_VBG and_CC not_RB transdominant_JJ ._SENT It_PP appears_VBZ that_IN ,_, in_IN addition_NN to_TO the_DT G354A_NP mutation_NN itself_PP ,_, a_DT region_NN C-terminal_JJ to_TO the_DT G354A_NP mutation_NN (_( residues_NNS 354_CD to_TO 450_CD )_) is_VBZ required_VBN for_IN potentiation_NN ._SENT Interestingly_RB ,_, neither_CC the_DT G354A_NP mutation_NN nor_CC the_DT region_NN encompassing_VBG amino_NN acids_NNS 355_CD to_TO 450_CD was_VBD sufficient_JJ to_TO confer_VB potentiation_NN when_WRB present_NN alone_RB ._SENT The_DT G354A_NP mutation_NN may_MD introduce_VB a_DT conformational_JJ change_NN which_WDT leads_VBZ to_TO destabilization_NN of_IN the_DT protein_NN ._SENT The_DT 355_CD to_TO 450_CD region_NN may_MD be_VB involved_VBN in_IN protein-protein_NN interactions_NNS within_IN the_DT UL9_NP dimer_NN ._SENT Overexpression_NN of_IN UL9-MV_NP influences_VBZ wild-type_NP UL9_NP protein_NN levels_NNS and_CC is_VBZ able_JJ to_TO override_VB the_DT inhibitory_JJ effect_NN of_IN UL9_NP ._SENT |_SYM Since_IN the_DT overexpression_NN of_IN wild-type_NP UL9_NP is_VBZ inhibitory_JJ for_IN HSV-1_JJ infection_NN ,_, the_DT potentiation_NN phenotype_NN of_IN UL9-MV_NP may_MD be_VB a_DT result_NN of_IN removal_NN of_IN UL9_NP during_IN the_DT course_NN of_IN infection_NN ,_, thereby_RB preventing_VBG wild-type_NN UL9_NN from_IN exercising_VBG its_PP$ inhibitory_JJ effect_NN ._SENT In_IN order_NN to_TO test_VB this_DT hypothesis_NN ,_, wild-type_NP UL9_NP and_CC UL9-MV_NP were_VBD cotransfected_VBN in_IN a_DT ratio_NN of_IN 1:15_CD ,_, and_CC the_DT steady-state_NN levels_NNS of_IN full-length_JJ UL9_NP were_VBD followed_VBN by_IN Western_JJ blot_NN ._SENT Figure_NN shows_VBZ that_IN the_DT overexpression_NN of_IN UL9-MV_NP resulted_VBD in_IN lower_JJR steady-state_NN levels_NNS of_IN wild-type_NN UL9_NN (_( compare_VB lanes_NNS 2_CD and_CC 3_CD )_) ._SENT In_IN order_NN to_TO determine_VB whether_IN destabilization_NN would_MD also_RB occur_VB in_IN the_DT context_NN of_IN infection_NN ,_, Vero_NP cells_NNS were_VBD transfected_VBN with_IN wild-type_NP UL9_NP and_CC UL9-MV_NP (_( ratio_NN ,_, 1:15_CD )_) and_CC 24_CD h_NN later_RBR were_VBD superinfected_VBN with_IN the_DT UL9_NP null_JJ virus_NN hr94_NN ._SENT In_IN both_DT experiments_NNS ,_, shown_VBN in_IN Fig._NN ,_, lanes_NNS 1_CD to_TO 4_CD (_( transfection_NN )_) ,_, and_CC Fig._NN ,_, lanes_NNS 5_CD to_TO 8_CD (_( transfection_NN and_CC hr94_NN superinfection_NN )_) ,_, the_DT level_NN of_IN full-length_JJ UL9_NP was_VBD lowered_VBN approximately_RB two-_NN to_TO threefold_RB ,_, as_IN estimated_VBN from_IN control_NN Western_JJ blots_NNS in_IN which_WDT various_JJ amounts_NNS of_IN UL9_NP protein_NN were_VBD analyzed_VBN for_IN comparison_NN ._SENT The_DT possibility_NN that_IN the_DT decrease_NN in_IN levels_NNS of_IN full-length_JJ UL9_NP protein_NN was_VBD due_JJ to_TO transfection_NN of_IN large_JJ amounts_NNS of_IN plasmid_NP (_( a_DT total_NN of_IN 16_CD mug_NN per_IN 60-mm2_JJ plate_NN )_) was_VBD ruled_VBN out_RP by_IN transfecting_VBG the_DT cells_NNS with_IN the_DT same_JJ amount_NN of_IN empty_JJ plasmid_NN in_IN combination_NN with_IN wild-type_NP UL9_NP (_( Fig._NN ,_, lanes_NNS 3_CD and_CC 7_CD )_) ._SENT In_IN order_NN to_TO determine_VB whether_IN the_DT overexpression_NN of_IN UL9-MV_NP resulted_VBD in_IN the_DT decrease_NN in_IN levels_NNS of_IN an_DT unrelated_JJ protein_NN ,_, the_DT same_JJ experiment_NN was_VBD performed_VBN but_CC the_DT levels_NNS UL6_NP ,_, an_DT HSV-1_NP protein_NN essential_JJ for_IN cleavage_NN and_CC packaging_NN ,_, were_VBD monitored_VBN (_( Fig._NN ,_, lanes_NNS 9_CD to_TO 12_CD )_) ._SENT The_DT overexpression_NN of_IN UL9-MV_NP did_VBD not_RB lower_JJR UL6_NP steady-state_NN protein_NN levels_NNS ._SENT In_IN summary_NN ,_, we_PP found_VBD that_DT overexpression_NN of_IN UL9-MV_NP reproducibly_RB lowered_VBD the_DT levels_NNS of_IN wild-type_NN UL9_NN in_IN the_DT context_NN of_IN both_DT transfection_NN and_CC infection_NN ._SENT To_TO ask_VB whether_IN the_DT decrease_NN in_IN steady-state_NN levels_NNS of_IN UL9_NP also_RB correlated_VBD with_IN the_DT potentiation_NN phenotype_NN ,_, the_DT same_JJ experiment_NN was_VBD performed_VBN in_IN the_DT context_NN of_IN the_DT plaque_NN reduction_NN assay_NN ._SENT In_IN this_DT case_NN ,_, Vero_NP cells_NNS were_VBD cotransfected_VBN with_IN wild-type_JJ HSV-1_JJ infectious_JJ DNA_NN and_CC plasmids_NNS encoding_VBG wild-type_NP UL9_NP and_CC UL9-MV_NP in_IN a_DT ratio_NN of_IN 1:10:150_CD ._SENT As_IN shown_VBN in_IN Fig._NN ,_, wild-type_NP UL9_NP had_VBD an_DT inhibitory_JJ effect_NN on_IN plaque_NN formation_NN ,_, but_CC the_DT overexpression_NN of_IN UL9-MV_NP overrode_VBD the_DT inhibition_NN ._SENT Interestingly_RB ,_, cotransfection_NN of_IN wild-type_NP UL9_NP and_CC UL9-MV_NP with_IN wild-type_NP HSV-1_NP infectious_JJ DNA_NN resulted_VBN in_IN even_RB greater_JJR plaque_NN numbers_NNS compared_VBN to_TO the_DT same_JJ experiment_NN in_IN which_WDT wild-type_NP UL9_NP was_VBD omitted_VBN (_( Fig._NN ,_, compare_VBP the_DT third_JJ and_CC second_JJ bars_NNS )_) ._SENT This_DT further_JJR stimulation_NN in_IN the_DT presence_NN of_IN wild-type_NP UL9_NP may_MD be_VB due_JJ to_TO differences_NNS in_IN the_DT timing_NN of_IN expression_NN of_IN UL9_NP from_IN plasmids_NNS compared_VBN to_TO expression_NN from_IN the_DT viral_JJ genome_NN ._SENT It_PP may_MD reflect_VB the_DT earlier_JJR activation_NN of_IN a_DT degradation_NN pathway_NN which_WDT acts_VBZ to_TO lower_VB the_DT steady-state_NN levels_NNS of_IN UL9_NP (_( see_VB below_IN )_) ._SENT In_IN any_DT case_NN ,_, these_DT experiments_NNS indicate_VBP that_IN the_DT potentiation_NN phenotype_NN of_IN the_DT UL9-MV_NP mutant_NN is_VBZ inversely_RB related_VBN to_TO the_DT protein_NN levels_NNS of_IN wild-type_NN UL9_NP ._SENT Indirect_JJ evidence_NN that_IN UL9_NP NTD_NP and_CC UL9-MV_NP are_VBP able_JJ to_TO interact_VB with_IN full-length_JJ UL9_NP ._SENT |_SYM Our_NN finding_VBG that_IN UL9-MV_NP lowers_VBZ the_DT steady-state_NN protein_NN levels_NNS of_IN 